Clinical Trial

Efficacy and Safety of Pracytarabine Versus Regorafenib in the Treatment of Patients With Hepatocellular Carcinoma

Active, Not Recruiting Phase 2/3
View on ClinicalTrials.gov →
Summary
This is a Phase 2/3 study evaluating the efficacy and safety of Pracytarabine versus regorafenib in patients with advanced hepatocellular carcinoma (HCC) who have experienced treatment failure with standard systemic therapies involving targeted drugs and immune checkpoint inhibitors, or dual immune checkpoint inhibitors.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2025-12-09.
Trial Details
NCT Number NCT07300488
Lead Sponsor Xi'an Xintong Pharmaceutical Research Co.,Ltd.
Conditions HCC
Enrollment 60 participants
Start Date 2025-09-01
Primary Completion 2027-02-28 (estimated)
Study Completion 2027-04-30 (estimated)
Updated on ClinicalTrials.gov 2025-12-31